ANI Pharmaceuticals, Inc.
ANIP
$82.72
-$0.05-0.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 20.46% | 29.64% | 53.58% | 53.12% | 43.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.46% | 29.64% | 53.58% | 53.12% | 43.43% |
| Cost of Revenue | 28.13% | 43.44% | 48.06% | 36.97% | 48.58% |
| Gross Profit | 15.95% | 21.65% | 57.67% | 63.65% | 40.57% |
| SG&A Expenses | -3.75% | 26.95% | 10.08% | 65.05% | 59.36% |
| Depreciation & Amortization | -8.61% | 0.06% | 43.71% | 58.41% | 55.87% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.60% | 24.98% | 29.30% | 55.70% | 49.56% |
| Operating Income | 174.47% | 78.42% | 334.81% | 26.47% | -6.33% |
| Income Before Tax | 101.24% | 328.74% | 207.31% | 560.21% | -21.11% |
| Income Tax Expenses | 149.16% | 214.43% | 197.97% | -- | -39.59% |
| Earnings from Continuing Operations | 88.07% | 367.52% | 210.14% | 473.81% | -13.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 88.07% | 367.52% | 210.14% | 473.81% | -13.87% |
| EBIT | 174.47% | 78.42% | 334.81% | 26.47% | -6.33% |
| EBITDA | 61.18% | 33.25% | 683.46% | 43.95% | 24.38% |
| EPS Basic | 87.54% | 323.43% | 193.59% | 902.61% | -16.50% |
| Normalized Basic EPS | 264.63% | 165.96% | 215.61% | 53.46% | -17.62% |
| EPS Diluted | 86.11% | 313.31% | 189.21% | 885.65% | -16.91% |
| Normalized Diluted EPS | 261.84% | 152.68% | 210.01% | 49.92% | -18.04% |
| Average Basic Shares Outstanding | 6.67% | 6.38% | 3.45% | 2.66% | 2.66% |
| Average Diluted Shares Outstanding | 7.47% | 11.98% | 8.70% | 5.11% | 3.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | 1.00% | 1.77% | 1.27% | 0.16% |